Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Abelcet tolerability study in cystic fibrosis patients with ABPA
2010-019194-15Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in allergic bronchopulmonary aspergillosis (ABPA) and cystic fibrosis (CF), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Renal safety adverse event. Started May 2010; status: active.
02
Drugs
amphotericin b
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-019194-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019194-15.